Home

HCW Biologics Inc. - Common Stock (HCWB)

0.2290
-0.0110 (-4.58%)
NASDAQ · Last Trade: Apr 4th, 7:57 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Investors are turning their attention to a lineup of Nasdaq-listed companies making waves in their respective industries.
Via AB Newswire · November 18, 2024
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors
By HCW Biologics, Inc · Via GlobeNewswire · November 8, 2023
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc.
By HCW Biologics, Inc · Via GlobeNewswire · November 1, 2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
By HCW Biologics, Inc · Via GlobeNewswire · September 6, 2023
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
Provides funding for buildout of new headquarters and manufacturing facility
By HCW Biologics, Inc · Via GlobeNewswire · April 27, 2023
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer
By HCW Biologics, Inc · Via GlobeNewswire · December 8, 2022